Birdwatch Archive

Birdwatch Note

2022-04-24 18:00:55 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING

A two-shot course of Pfizer Inc.’s vaccine may have just 22.5% efficacy against symptomatic infection with the omicron variant, but can thwart severe disease, according to laboratory experiments in South Africa. https://www.bloomberg.com/news/articles/2021-12-11/pfizer-course-has-23-efficacy-vs-omicron-in-s-african-study

Written by 398E7AC1E8E6D9E45ED959A012C30C68
Participant Details

All Information

• ID - 1518288895741509633
• noteId - 1518288895741509633
• participantId - 398E7AC1E8E6D9E45ED959A012C30C68
• noteAuthorParticipantId -
• createdAtMillis - 1650823255845
• tweetId - 1377618480527257606
• classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
• believable - BELIEVABLE_BY_MANY
• harmful - CONSIDERABLE_HARM
• validationDifficulty - CHALLENGING
• misleadingOther - 0
• misleadingFactualError - 1
• misleadingManipulatedMedia - 0
• misleadingOutdatedInformation - 0
• misleadingMissingImportantContext - 0
• misleadingUnverifiedClaimAsFact - 0
• misleadingSatire - 0
• notMisleadingOther - 0
• notMisleadingFactuallyCorrect - 0
• notMisleadingOutdatedButNotWhenWritten - 0
• notMisleadingClearlySatire - 0
• notMisleadingPersonalOpinion - 0
• trustworthySources - 1
• summary
• A two-shot course of Pfizer Inc.’s vaccine may have just 22.5% efficacy against symptomatic infection with the omicron variant, but can thwart severe disease, according to laboratory experiments in South Africa. https://www.bloomberg.com/news/articles/2021-12-11/pfizer-course-has-23-efficacy-vs-omicron-in-s-african-study